---
annotation-target: blood.2021013658.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-16T09:30:10.116Z","text":"2014年1月10日美国食品药品监督管理局(FDA)批准曲美替尼与达拉非尼联用治疗有不可切除的(不能外科手术)和转移晚期黑色素瘤患者。达拉非尼不适用于野生型BRAF-患者的治疗。","updated":"2022-09-16T09:30:10.116Z","document":{"title":"blood.2021013658.pdf","link":[{"href":"urn:x-pdf:50165fb3cd0f2e51151bbd9c6af8fcbe"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf"}],"documentFingerprint":"50165fb3cd0f2e51151bbd9c6af8fcbe"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","selector":[{"type":"TextPositionSelector","start":140,"end":167},{"type":"TextQuoteSelector","exact":"Dabrafenib plus trametinib ","prefix":"776-0545editorial@hematology.org","suffix":"in patients with relapsed/refrac"}]}]}
>```
>%%
>*%%PREFIX%%776-0545editorial@hematology.org%%HIGHLIGHT%% ==Dabrafenib plus trametinib== %%POSTFIX%%in patients with relapsed/refrac*
>%%LINK%%[[#^1s0nne3hkgf|show annotation]]
>%%COMMENT%%
>2014年1月10日美国食品药品监督管理局(FDA)批准曲美替尼与达拉非尼联用治疗有不可切除的(不能外科手术)和转移晚期黑色素瘤患者。达拉非尼不适用于野生型BRAF-患者的治疗。
>%%TAGS%%
>
^1s0nne3hkgf


>%%
>```annotation-json
>{"created":"2022-09-16T09:41:42.566Z","updated":"2022-09-16T09:41:42.566Z","document":{"title":"blood.2021013658.pdf","link":[{"href":"urn:x-pdf:50165fb3cd0f2e51151bbd9c6af8fcbe"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf"}],"documentFingerprint":"50165fb3cd0f2e51151bbd9c6af8fcbe"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","selector":[{"type":"TextPositionSelector","start":10955,"end":11229},{"type":"TextQuoteSelector","exact":"Dabrafenib + trametinib showed durable responses with a manageable safety profile in patients with relapsed/refractory BRAF V600E-mutant HCL •  This combination should be considered a meaningful therapeutic option for patients with relapsed/refractory BRAF V600E-mutant HCL ","prefix":"022             3 Key points •  ","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%022             3 Key points •%%HIGHLIGHT%% ==Dabrafenib + trametinib showed durable responses with a manageable safety profile in patients with relapsed/refractory BRAF V600E-mutant HCL •  This combination should be considered a meaningful therapeutic option for patients with relapsed/refractory BRAF V600E-mutant HCL== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^c1tlzsz9but|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^c1tlzsz9but


>%%
>```annotation-json
>{"created":"2022-09-16T09:49:59.067Z","updated":"2022-09-16T09:49:59.067Z","document":{"title":"blood.2021013658.pdf","link":[{"href":"urn:x-pdf:50165fb3cd0f2e51151bbd9c6af8fcbe"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf"}],"documentFingerprint":"50165fb3cd0f2e51151bbd9c6af8fcbe"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","selector":[{"type":"TextPositionSelector","start":11401,"end":11622},{"type":"TextQuoteSelector","exact":"BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy  and  safety  of  dabrafenib  plus  trametinib  in  patients  with  relapsed/refractory  BRAF V600E  mutation-positive  ","prefix":"ber 2022             4 Abstract ","suffix":"HCL.  This  open-label,  phase  "}]}]}
>```
>%%
>*%%PREFIX%%ber 2022             4 Abstract%%HIGHLIGHT%% ==BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy  and  safety  of  dabrafenib  plus  trametinib  in  patients  with  relapsed/refractory  BRAF V600E  mutation-positive== %%POSTFIX%%HCL.  This  open-label,  phase*
>%%LINK%%[[#^n7htpihibtr|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^n7htpihibtr


>%%
>```annotation-json
>{"created":"2022-09-16T09:51:12.149Z","updated":"2022-09-16T09:51:12.149Z","document":{"title":"blood.2021013658.pdf","link":[{"href":"urn:x-pdf:50165fb3cd0f2e51151bbd9c6af8fcbe"},{"href":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf"}],"documentFingerprint":"50165fb3cd0f2e51151bbd9c6af8fcbe"},"uri":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220916/blood.2021013658.pdf","selector":[{"type":"TextPositionSelector","start":12282,"end":13354},{"type":"TextQuoteSelector","exact":" Fifty-five  patients  with BRAF  V600E  mutation-positive  HCL  were  enrolled.  The investigator-assessed ORR was 89.0% (95% confidence interval [CI], 77.8%–95.9%); 65.5% of patients  had  a  complete  response  (without  minimal  residual  disease  [MRD]:  9.1%  [negative immunohistochemistry  of  bone  marrow  {BM}  biopsy],  12.7%  [negative  BM  aspirate  flow cytometry  {FC}],  16.4%  [negative  immunohistochemistry  and/or  FC  results];  with  MRD,  49.1%) and 23.6% had a partial response. The 24-month DOR was 97.7% with 24-month PFS and OS rates of 94.4% and 94.5%, respectively. The most common treatment-related adverse events were pyrexia (58.2%), chills (47.3), and hyperglycemia (40.0). Dabrafenib plus trametinib demonstrated  durable  responses  with  a  manageable  safety  profile  consistent  with  previous observations in other indications and should be considered as a rituximab-free therapeutic option for patients with relapsed/refractory BRAF V600E mutation-positive HCL. This trial is registered at www.clinicaltrials.gov as #NCT02034110. ","prefix":"rall survival (OS), and safety. ","suffix":"Downloaded from http://ashpublic"}]}]}
>```
>%%
>*%%PREFIX%%rall survival (OS), and safety.%%HIGHLIGHT%% ==Fifty-five  patients  with BRAF  V600E  mutation-positive  HCL  were  enrolled.  The investigator-assessed ORR was 89.0% (95% confidence interval [CI], 77.8%–95.9%); 65.5% of patients  had  a  complete  response  (without  minimal  residual  disease  [MRD]:  9.1%  [negative immunohistochemistry  of  bone  marrow  {BM}  biopsy],  12.7%  [negative  BM  aspirate  flow cytometry  {FC}],  16.4%  [negative  immunohistochemistry  and/or  FC  results];  with  MRD,  49.1%) and 23.6% had a partial response. The 24-month DOR was 97.7% with 24-month PFS and OS rates of 94.4% and 94.5%, respectively. The most common treatment-related adverse events were pyrexia (58.2%), chills (47.3), and hyperglycemia (40.0). Dabrafenib plus trametinib demonstrated  durable  responses  with  a  manageable  safety  profile  consistent  with  previous observations in other indications and should be considered as a rituximab-free therapeutic option for patients with relapsed/refractory BRAF V600E mutation-positive HCL. This trial is registered at www.clinicaltrials.gov as #NCT02034110.== %%POSTFIX%%Downloaded from http://ashpublic*
>%%LINK%%[[#^397pwzyfzb|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^397pwzyfzb
